RxDoctor Payments Data

Gloria Nnah

Psychiatric/Mental Health · Elkridge, MDNPI 1336803550

Payments from drug & device makers

$1,403in general payments, 2019–2025

Across 31 payments — averaging $45.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$443
  • Johnson & Johnson$430
  • Neurocrine Biosciences, Inc.$266
  • E.r. Squibb & Sons, L.L.C.$156
  • Otsuka America Pharmaceutical, Inc.$59
  • Lundbeck LLC$50

What the payments were for

  • Food & beverage$1,398100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,403 in reported general payments places this provider in the 80th percentile of 1,461 psychiatric/mental health providers in Maryland.

See all psychiatric/mental health providers in Maryland

Medicare billing

Part B allowed, 2024
$88,066
Medicare patients
101
Services billed
1,297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate18$36,475
Oxcarbazepine35$4,004
Clozapine21$2,006
Fluphenazine Hcl11$1,541
Perphenazine23$1,107
Divalproex Sodium31$911
Benztropine Mesylate56$671
Olanzapine23$532
Gabapentin23$482
Trazodone Hcl41$354
Hydroxyzine Hcl19$332
Lamotrigine ErLamotrigine11$300
Sertraline Hcl50$286
Risperidone35$281
Doxepin Hcl15$275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$430$36,47518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,461 psychiatric/mental health providers in Maryland.

Other psychiatric/mental health in Elkridge

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →